AMGEN INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.56 BRL | +18.33% |
|
+2.34% | +17.24% |
| 06-14 | Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto | DJ |
| 06-14 | Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 803B | ||||||
| 629B | ||||||
| 351B | - | - | - | - | ||
| 324B | ||||||
| 303B |
